...
首页> 外文期刊>European Heart Journal: The Journal of the European Society of Cardiology >Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: A human study using a multi-parametric cardiovascular magnetic resonance imaging approach
【24h】

Imaging of myocardial infarction using ultrasmall superparamagnetic iron oxide nanoparticles: A human study using a multi-parametric cardiovascular magnetic resonance imaging approach

机译:使用超小型超顺磁性氧化铁纳米颗粒对心肌梗死进行成像:一项使用多参数心血管磁共振成像方法进行的人体研究

获取原文
获取原文并翻译 | 示例
           

摘要

AimsThe purpose of this clinical trial was to investigate whether cardiovascular magnetic resonance imaging (CMR) using ferumoxytol (Feraheme?, FH), an ultrasmall superparamagnetic iron oxide nanoparticle (USPIO), allows more detailed characterization of infarct pathology compared with conventional gadolinium-based necrosis/fibrosis imaging in patients with acute myocardial infarction.Methods and resultsFourteen patients who had experienced an acute ST-elevation myocardial infarction were included in this study. Following coronary angiography, a first baseline study (pre-FH) was performed followed by subsequent CMR studies (post-FH) 48 h after intravenous ferumoxytol administration. The CMR studies comprised cine-CMR, T 2-weighted short tau inversion recovery spin echo imaging, T 2*-mapping, and T1-weighted late gadolinium enhancement (LGE) imaging. The median extent of short-axis in-plane LGE was 30% [inter-quartile range (IQR) 26-40%]. The median in-plane extent of T 2-weighted 'hypoenhancement' in the region of myocardial infarction, which was not present prior to ferumoxytol administration in any patient, was 19% (IQR 14-22%; P 0.001 compared with the extent of LGE). The median in-plane extent of areas showing signal void in T2*-mapping images post-FH in the region of myocardial infarction was 16% (IQR 12-18%; P 0.001 compared with the extent of LGE; P = 0.34 compared with the extent of T2-weighted hypoenhancement). A substantial drop in absolute T 2*-values was observed not only in the infarct core and peri-infarct zone, but also in the remote 'healthy' myocardium, although there was only a minor change in the skeletal muscle. Substantial ferumoxytol uptake was detected only in cultured macrophages, but not in peripheral blood monocytes from study patients.ConclusionWe could demonstrate in humans that USPIO-based contrast agents enable a more detailed characterization of myocardial infarct pathology mainly by detecting infiltrating macrophages. Considering the multi-functionality of USPIO-based particles and their superior safety profile compared with gadolinium-based compounds, these observations open up new vistas for the clinical application of USPIO.
机译:目的本临床试验的目的是研究使用超细超顺磁性氧化铁纳米粒子-阿魏酸(Ferhemeto,FH)进行的心血管磁共振成像(CMR)与传统的基于ne的坏死相比是否能够更详细地表征梗塞病理方法和结果本研究纳入了14例急性ST段抬高型心肌梗死患者。冠状动脉造影后,进行首次基线研究(FH之前),然后在静脉内给予阿魏酸48小时后进行随后的CMR研究(FH之后)。 CMR研究包括电影CMR,T 2加权的短tau反转恢复自旋回波成像,T 2 *映射和T1加权的晚期g增强(LGE)成像。短轴平面LGE的中位数范围为30%[四分位间距(IQR)26-40%]。心肌梗塞区域中T 2加权的“ hypoenhancement”的平均平面内范围为19%(IQR 14-22%; P <0.001,与该范围相比,在任何患者中均未接受阿魏酸给予之前存在) LGE)。心肌梗死区域在FH之后的T2 *图像中显示信号无效的区域的平面中值范围为16%(IQR 12-18%;与LGE的程度相比,P <0.001;与PGE相比,P = 0.34以及T2加权过高的程度)。尽管在骨骼肌中只有很小的变化,但不仅在梗塞核心和梗塞周围区域,而且在遥远的“健康”心肌中,绝对T 2 *值均显着下降。仅在培养的巨噬细胞中检测到大量阿魏木酚摄取,而在研究患者的外周血单核细胞中未检测到。结论我们可以在人类中证明基于USPIO的造影剂主要通过检测浸润性巨噬细胞来使心肌梗塞病理学更详细地表征。考虑到USPIO基颗粒的多功能性以及与g基化合物相比优越的安全性,这些发现为USPIO的临床应用开辟了新的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号